Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04440358
Recruitment Status : Recruiting
First Posted : June 19, 2020
Last Update Posted : December 7, 2021
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

Condition or disease Intervention/treatment Phase
Recurrent Glioblastoma Device: Exablate BBBD Drug: Carboplatin Phase 1 Phase 2

Detailed Description:
This is a Phase 1/2, open-label, prospective, multi-center, single-arm study to establish the safety and feasibility of blood-brain-barrier disruption (BBBD) combined with intravenous carboplatin for the treatment of rGBM using the Exablate Neuro Model 4000 Type 2 system. Adult glioblastoma subjects that are planned for carboplatin chemotherapy will be considered for study enrollment. Eligible subjects will undergo up to 6 cycles of Exablate BBBD procedures in conjunction with carboplatin chemotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Actual Study Start Date : October 13, 2020
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Carboplatin

Arm Intervention/treatment
Experimental: Exablate BBBD with carboplatin
Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
Device: Exablate BBBD
BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
Other Name: Exablate Neuro

Drug: Carboplatin
Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain

Primary Outcome Measures :
  1. Occurrence of Adverse Events [ Time Frame: Through study completion, an average of 12 months ]
    All adverse events and/or Serious Adverse Events will be documented and reported according to CTCAE criteria

  2. Contrast intensity on MR imaging [ Time Frame: Immediately after Exablate BBBD procedure ]
    BBBD will be determined by contrast intensity in sonicated areas on T1 weighted gadolinium-based MR imaging

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be between 18-80 years old
  • Histologically confirmed glioblastoma
  • Planned for Carboplatin monotherapy
  • Be willing and able to provided written informed consent/assent
  • Tumor progression after first line therapy
  • Recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy
  • Women of childbearing potential is confirmed not pregnant. Male and Female subjects utilize highly effective contraception
  • Able to communicate verbally

Exclusion Criteria:

  • Acute intracranial hemorrhage
  • Ferrous metallic implanted objects in the skull or brain
  • Prior toxicity with carboplatin chemotherapy
  • Women who are pregnant or breastfeeding
  • Cerebellar spinal cord or brain stem tumor
  • Known active Hepatitis B or Hepatitis C or HIV
  • Significant depression not adequately controlled
  • Cardiac disease or unstable hemodynamics
  • Severe hypertension
  • History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage
  • Active drug or alcohol use disorder
  • Known sensitivity to gadolinium-based contrast agents
  • Known sensitivity or contraindications to ultrasound contrast agent or perflutren
  • Unable to undergo MRI or contraindications to MRI such as non-MRI compatible implanted devices
  • Difficulty lying supine and still or severe claustrophobia which cannot be managed with medication
  • Severely impaired renal function
  • Right to left or bi-directional cardiac shunt
  • Cranial or systemic infection requiring antibiotics
  • Known additional malignancy that is progression or require active treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04440358

Layout table for location contacts
Contact: Julia Zhu 972 421 0180
Contact: Kathy McDermott

Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Maheleth Llinas    +1-416-480-6100 ext 2476   
Principal Investigator: Nir Lipsman, MD         
Sheba Medical Center Recruiting
Tel Hashomer, Israel, 52621
Contact: Meirav Shinberger    +972-546889727      
Principal Investigator: Zion Zibly, MD         
Fondazione IRCCS Neurologico Carlo Besta Recruiting
Milano, Italy, 20133
Contact: Giorgia Simonetti    +39 022394-2440   
Principal Investigator: Antonio Silvani, MD         
Korea, Republic of
Yonsei University Medical Center Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Eun Jung Kweon, RN    82-2-2227-4578   
Principal Investigator: Jin Woo Chang, MD         
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: InSightec Identifier: NCT04440358    
Other Study ID Numbers: BT009 [OUS]
First Posted: June 19, 2020    Key Record Dates
Last Update Posted: December 7, 2021
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by InSightec:
Focused Ultrasound
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents